

February 5, 2025

To

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

To

The Corporate Relations Department

BSE LIMITED

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street,

MUMBAI -400 001

Company Code No. AUROPHARMA

Company Code No. 524804

Dear Sir/ Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015

This is to inform you that the Company has received an order from the Additional Commissioner of Central Tax, Ranga Reddy GST Commissionerate, Hyderabad, passed under relevant provisions of the Central Goods and Services Tax Act, 2017 for the period 2017-18 to 2021-22 demanding GST along with interest and penalty.

The details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed herewith as **Annexure.**

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

Encl.: Annexure

(CIN: L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED



Annexure

S. No.	Particulars	Details
1	Name of the authority	Additional Commissioner of Central Tax, Ranga Reddy GST Commissionerate, Hyderabad
2	Nature and details of the action(s) taken, initiated or order(s) passed by the Authority	Order passed under relevant provisions of the Central Goods and Services Tax Act, 2017 for the period 2017-18 to 2021-22 demanding GST of Rs. 77,61,35,242/- along with interest. Further, a penalty of Rs. 77,61,35,242/- was imposed. The amount of Rs. 23,71,71,782/- paid under protest by the Company and ITC of Rs. 8,78,23,385 reversed by the Company, were ordered for appropriation.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority.	Order dated 28.01.2025 was received by the Company on February 4, 2025.
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	The authority has passed the said order on the contention that the Company has received excess IGST refund (CIF vs FOB); non-surrender of IGST on short realization of export proceeds in respect of exports made during 01.07.2017 to 23.03.2020 and non-reversal of ITC in terms of Rule 37 of CGST Rules. The Company is intending to file an appeal before the Appellate Authority.
5	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact on the Company's financials or operations due to the said Order.

AUROBINDO PHARMA LIMITED

(CIN: L24239TG1986PLC015190)